GlutaBoost works differently, it helps stop the damage you cant see yet
Afamelanotide is FDA-approved for EPP at 16 mg subcutaneous implant every 60 days roughly 2 mg/day of continuous release (Langendonk et al., 2015)
Figure 1 ME/CFS symptoms ME/CFS is a heterogeneous disease (16, 20), meaning that patients display varying symptoms and several body systems are impacted (11)
2 4 Studies also show that BPC-157 reduces scar formation and portal hypertension after liver cirrhosis, about as far from skin and tendon as you can get
Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, Heuvel van den LP, et al: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase
Journal of Food Composition and Analysis, 86: 103353, ISSN: 0889-1575